Climb Bio
climbbio.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$363.2M
7 rounds on record
Latest round
$110.1M
Venture round · Apr 2026 · 5 mo ago
Backers
1
RA Capital Management
The money's age
Fresh money
5 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 29
Raised a round Venture round $110.1M · SEC Form D
Jun 27, 2024
Raised a round Venture round $120M · SEC Form D
Jun 27, 2024
Raised a round Venture round $41.9M · SEC Form D
May 21, 2021
Raised a round Venture round $60M · SEC Form D
Oct 16, 2020
Raised a round Venture round $5M · SEC Form D
Oct 10, 2019
Raised a round Venture round $10M · SEC Form D
Feb 4, 2019
Raised a round Venture round $16.3M · SEC Form D
2018
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2026 | $110.1M | — | SEC Form D |
| Venture round | Jun 2024 | $41.9M | — | SEC Form D |
| Venture round | Jun 2024 | $120M | — | SEC Form D |
| Venture round | May 2021 | $60M | — | SEC Form D |
| Venture round | Oct 2020 | $5M | — | SEC Form D |
| Venture round | Oct 2019 | $10M | — | SEC Form D |
| Venture round | Feb 2019 | $16.3M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Climb Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Aoife BrennanExecutive Officer, DirectorSEC Form D
Perrin WilsonExecutive OfficerSEC Form D
Susan AltschullerExecutive OfficerSEC Form D
Andrew LevinDirectorSEC Form D
Julio VegaExecutive OfficerSEC Form D
Valerie MorissetExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management Investors in similar startupsfunds that back the companies most like this one
backs PROVEN Skincare
backs WorkBoard
backs WorkBoard
backs WorkBoard
backs Bigwhalelabs
backs WorkBoard
Similar startupsby what they do, their industry and backers
Your system of record for strategy and goals with AI agents that do the work. Every manager gets a Chief of Staff and Leadership Coach…
Reperio is the world's only at-home health screening kit with instant results. No more waiting for lab results!
Shopfully. The leading tech company in Drive To Store. We work with the best tech and people to reinvent local shopping and take it to the…
Co-creating video content with your community empowers even the smallest teams to achieve more with less. See how 100+ organizations are…
Personalized skincare that adapts to your skin, lifestyle, and environment. High-potency, science-backed formulas with real results — no…
Big Whale Labs builds products to achieve financial AGI — the superintelligence of money.
News
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 ...
Read more
Report
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
29-day half-life
Read more
Report
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
--Climb Bio, Inc., a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2026, and provided business updates. "2026 is proving to b
Read more
Report
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development
Read more
Report
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Read more
Report
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
Read more
Report
Climb Bio, Inc. Expands B-cell Targeted Therapeutics Pipeline with Exclusive License for CLYM116, an Anti-APRIL Monoclonal Antibody
Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025.
Read more
Report
Climb Bio to be Added to the Nasdaq Biotechnology Index
WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 - Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq i
Read more
Report
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing! The post Hello world! appeared first on Climb Bio.
Read more
Report
People
Aoife Brennan
Executive Officer, Director
Perrin Wilson
Executive Officer
Susan Altschuller
Executive Officer
Andrew Levin
Director
Julio Vega
Executive Officer
Valerie Morisset
Executive Officer
James Bucher
Executive Officer
Robert Azelby
Executive Officer, Director
Erin Lavelle
Executive Officer
Stephen Thomas
Director
Douglas Williams
Director
Kimberlee Drapkin
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Boston
United States
HQ
Thomas
United States
Regional office
Stephen Thomas, PhD
20 William Street, Suite G50 • Wellesley Hills, MA 02481
Wellesley
United States
Regional office
Contact Us
20 William Street, Suite G50, Wellesley Hills, MA 02481
Financials
Total raised
$363.2M
Latest round
Venture - Series Unknown
Funding rounds
7
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $110.1M | Details |
| Venture - Series Unknown | 2024 | $41.9M | Details |
| Venture - Series Unknown | 2024 | $120M | Details |
| Venture - Series Unknown | 2021 | $60M | Details |
| Venture - Series Unknown | 2020 | $5M | Details |
| Venture - Series Unknown | 2019 | $10M | Details |
| Venture - Series Unknown | 2019 | $16.3M | Details |